AMRX icon

Amneal Pharmaceuticals

7.73 USD
-0.18
2.28%
At close Feb 14, 4:00 PM EST
After hours
7.73
+0.00
0.00%
1 day
-2.28%
5 days
-2.15%
1 month
-1.53%
3 months
-14.11%
6 months
-1.02%
Year to date
-0.39%
1 year
32.82%
5 years
57.43%
10 years
-48.50%
 

About: Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 7,700

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

31% more capital invested

Capital invested by funds: $900M [Q2] → $1.18B (+$279M) [Q3]

26% more call options, than puts

Call options by funds: $609K | Put options by funds: $483K

8% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 25

7% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 59

0% more funds holding

Funds holding: 181 [Q2] → 181 (+0) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0.16% less ownership

Funds ownership: 46.29% [Q2] → 46.13% (-0.16%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for AMRX.

Financial journalist opinion

Based on 5 articles about AMRX published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know
The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know
Neutral
Zacks Investment Research
2 weeks ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Neutral
Business Wire
2 weeks ago
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
Neutral
Business Wire
3 weeks ago
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie's NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis' AFINITOR DISPERZ®. In addition, the FDA has granted tentative approval to Amneal's rifaximin 550 mg oral tablets, whic.
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
Positive
Zacks Investment Research
1 month ago
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
1 month ago
Amneal (AMRX) Upgraded to Strong Buy: Here's Why
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Amneal (AMRX) Upgraded to Strong Buy: Here's Why
Neutral
Business Wire
2 months ago
Amneal to Participate at Upcoming Investor Conferences
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conferences.
Amneal to Participate at Upcoming Investor Conferences
Neutral
Business Wire
2 months ago
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Positive
Zacks Investment Research
3 months ago
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?
Charts implemented using Lightweight Charts™